Greg Scutt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Greg Scutt has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Andrew Overall
Medicines Optimisation Research and Enterprise Group, School of Applied Sciences, University of Brighton, UK
3 shared publications- Bhavik Anil Patel
University of Brighton
2 shared publications Chakravarthi Rajkumar
Brighton and Sussex Medical School, Brighton, UK
2 shared publications- David Waxman
Centre for Computational Systems Biology, ISTBI, Fudan University, Shanghai, China
2 shared publications Juliet Wright
Brighton and Sussex Medical School, Brighton, UK
2 shared publications- Marcus C. Allen
School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (1) , 93-104
Development of a translational strategy for using TIMP-3 to inhibit aggrecanase activity in osteoarthritis
- 8 September 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (1) , 93-104
Open AccessDevelopment of a translational strategy for using TIMP-3 to inhibit aggrecanase activity in osteoarthritis
- Open Access
- 11 December 2021
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 5, 100096
Clinical decision-making and dispensing performance in pharmacy students and its relationship to executive function and implicit memory
- 11 December 2021
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 5, 100096
Open AccessClinical decision-making and dispensing performance in pharmacy students and its relationship to executive function and implicit memory
- 1 May 2021
- Published by Elsevier in Journal of Infection
- Vol. 82 (5) , e18-e19
Single nucleotide polymorphisms in key aging pathways, and phenotypic markers of frailty are associated with increased odds of hospital admission with COVID-19
- 1 May 2021
- Published by Elsevier in Journal of Infection
- Vol. 82 (5) , e18-e19
Single nucleotide polymorphisms in key aging pathways, and phenotypic markers of frailty are associated with increased odds of hospital admission with COVID-19
- 9 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (9) , 3518-3530
Improved estimates of mean pharmacokinetic parameters for increased accuracy in dosing and reduced risk to patients
AIM Pharmacokinetic equations, which relate different parameters of a single individual, are often applied to reported mean parameter‐values, with the aim of estimating the mean value of an unreported parameter. Due to population heterogeneity this approach generally leads to errors in their estimation. We provide details of this source of error. Our aim is to take into account the effects of population heterogeneity in commonly used pharmacokinetic models. This provides improved estimates and knowledge of the concentration of a drug in the plasma over time. METHODS Inequalities and approximations for corrected mean estimates are derived. These results are then applied to published clinical‐trial data to illustrate their accuracy in practical situations. RESULTS By using mean values within the pharmacokinetic equations for a single individual, we show that estimates of mean parameter‐values, for a variety of dosing regimens, generally have errors. Using published clinical trial data, we show that such estimates can systematically deviate from the exact mean value by up to 19%. We provide analytical results, which amount to inequalities when there are systematic deviations from exact results, along with approximate results that improve the accuracy of estimates. CONCLUSIONS Medical, pharmacy and nursing students should be educated about errors and inequalities that can arise when transforming reported mean values of pharmacokinetic parameters into the mean values of parameters that are required, but not reported. Using approximate results, that correct estimates of mean parameter values so that they more accurately reflect actual average values, may provide a practical solution.
- 9 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (9) , 3518-3530
Improved estimates of mean pharmacokinetic parameters for increased accuracy in dosing and reduced risk to patients
AIM Pharmacokinetic equations, which relate different parameters of a single individual, are often applied to reported mean parameter‐values, with the aim of estimating the mean value of an unreported parameter. Due to population heterogeneity this approach generally leads to errors in their estimation. We provide details of this source of error. Our aim is to take into account the effects of population heterogeneity in commonly used pharmacokinetic models. This provides improved estimates and knowledge of the concentration of a drug in the plasma over time. METHODS Inequalities and approximations for corrected mean estimates are derived. These results are then applied to published clinical‐trial data to illustrate their accuracy in practical situations. RESULTS By using mean values within the pharmacokinetic equations for a single individual, we show that estimates of mean parameter‐values, for a variety of dosing regimens, generally have errors. Using published clinical trial data, we show that such estimates can systematically deviate from the exact mean value by up to 19%. We provide analytical results, which amount to inequalities when there are systematic deviations from exact results, along with approximate results that improve the accuracy of estimates. CONCLUSIONS Medical, pharmacy and nursing students should be educated about errors and inequalities that can arise when transforming reported mean values of pharmacokinetic parameters into the mean values of parameters that are required, but not reported. Using approximate results, that correct estimates of mean parameter values so that they more accurately reflect actual average values, may provide a practical solution.
- 1 April 2020
- Published by Elsevier in Resuscitation
- Vol. 149, 10-16
Safe prognostication following cardiac arrest: The role of the pharmacokinetics of fentanyl in patients treated with targeted temperature management
- 1 April 2020
- Published by Elsevier in Resuscitation
- Vol. 149, 10-16
Safe prognostication following cardiac arrest: The role of the pharmacokinetics of fentanyl in patients treated with targeted temperature management
- 1 October 2019
- Published by Elsevier in BioSystems
- Vol. 184, 103996
Estimating a drug’s elimination rate-constant or half-life from a single blood sample: a practical approach with particular benefits for critically ill/vulnerable patients
- 1 October 2019
- Published by Elsevier in BioSystems
- Vol. 184, 103996
Estimating a drug’s elimination rate-constant or half-life from a single blood sample: a practical approach with particular benefits for critically ill/vulnerable patients
- 18 May 2019
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 75 (6) , 1050-1057
The Association of a Single-Nucleotide Polymorphism in the Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene With Adverse Drug Reactions, Multimorbidity, and Frailty in Older People
Susceptibility to adverse drug reactions (ADRs), multimorbidity, and frailty are associated with human aging, yet there is wide variation in the severity and age at which individuals are afflicted. Identifying genetic markers of increased risk of this phenotype would help stratify individuals to specialist interventions. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) regulates a cell’s response to stressors, including the expression of enzymes involved in drug metabolism. Its expression has been shown to decline in animal aging models. In this study, we tested the hypothesis that Nrf2 gene (NFE2L2) transcription/translation decline in human aging and that single-nucleotide polymorphisms (SNPs) in the NFE2L2 gene are associated with increased ADR risk, multimorbidity, and frailty in older people. Gene expression and protein levels were measured in peripheral blood mononuclear cells donated from healthy patients aged 18–80 years old. NFE2L2 genotypes were determined at three loci in a subpopulation of patients recruited to the PRIME study (a multicenter prospective cohort study that followed older adults for 8 weeks post-discharge to determine ADR). Both NFE2L2 gene and Nrf2 protein expression declined significantly with age in human peripheral blood mononuclear cells. In the PRIME substudy population, the rs35652124 NFE2L2 SNP was associated with increased ADR risk and decreased frailty and multimorbidity scores.
- 18 May 2019
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 75 (6) , 1050-1057
The Association of a Single-Nucleotide Polymorphism in the Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene With Adverse Drug Reactions, Multimorbidity, and Frailty in Older People
Susceptibility to adverse drug reactions (ADRs), multimorbidity, and frailty are associated with human aging, yet there is wide variation in the severity and age at which individuals are afflicted. Identifying genetic markers of increased risk of this phenotype would help stratify individuals to specialist interventions. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) regulates a cell’s response to stressors, including the expression of enzymes involved in drug metabolism. Its expression has been shown to decline in animal aging models. In this study, we tested the hypothesis that Nrf2 gene (NFE2L2) transcription/translation decline in human aging and that single-nucleotide polymorphisms (SNPs) in the NFE2L2 gene are associated with increased ADR risk, multimorbidity, and frailty in older people. Gene expression and protein levels were measured in peripheral blood mononuclear cells donated from healthy patients aged 18–80 years old. NFE2L2 genotypes were determined at three loci in a subpopulation of patients recruited to the PRIME study (a multicenter prospective cohort study that followed older adults for 8 weeks post-discharge to determine ADR). Both NFE2L2 gene and Nrf2 protein expression declined significantly with age in human peripheral blood mononuclear cells. In the PRIME substudy population, the rs35652124 NFE2L2 SNP was associated with increased ADR risk and decreased frailty and multimorbidity scores.
- 1 April 2019
- Published by Elsevier in Thrombosis Research
- Vol. 176, 36-38
Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide
- 1 April 2019
- Published by Elsevier in Thrombosis Research
- Vol. 176, 36-38
Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide
- Open Access
- 5 June 2018
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 9 (8) , 415-424
Identification of clinical factors predicting warfarin sensitivity after cardiac surgery
Background: Warfarin is commonly initiated post-cardiac surgery to reduce the risk of intracardiac thrombus formation. Studies have found that sensitivity is increased after cardiac surgery and anticoagulation is subsequently difficult to manage. This study set out to identify clinical markers of increased warfarin sensitivity in patients after cardiac surgery, and build a model that can predict warfarin sensitivity, and improve safety in this setting. Methods: The study was an observational, retrospective cohort design. Clinical parameters including left ventricular ejection fraction (LVEF), cross-clamp time, age, serum albumin and C-reactive protein concentrations were collected from consenting patients who had undergone cardiac surgery and were prescribed postoperative warfarin. The warfarin dose index (WDI) was calculated for each patient from their international normalized ratio (INR) and warfarin dose, as a measure of sensitivity. Results: A total of 41 patients were recruited to the study. Logarithmically transformed WDI (log WDI) significantly correlated with LVEF, cardiopulmonary bypass (CPB) time, cross-clamp time, baseline INR and co-administration of amiodarone ( p < 0.05). When added to a linear regression model, LVEF and cross-clamp time produced a model that accounted for 41% of the variance in log WDI (R2 = 0.41), p = 0.0002). Applying a log WDI cutoff value of −0.349 discriminated between patients who develop an INR > 4 and those who do not, with a sensitivity of 75% and a specificity of 70%. Conclusions: This single-centre study has highlighted two risk factors for increased warfarin sensitivity post-cardiac surgery. Further research is needed to confirm these findings in a wider, more diverse population, and to validate this model.
- 5 June 2018
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 9 (8) , 415-424
Open AccessIdentification of clinical factors predicting warfarin sensitivity after cardiac surgery
Background: Warfarin is commonly initiated post-cardiac surgery to reduce the risk of intracardiac thrombus formation. Studies have found that sensitivity is increased after cardiac surgery and anticoagulation is subsequently difficult to manage. This study set out to identify clinical markers of increased warfarin sensitivity in patients after cardiac surgery, and build a model that can predict warfarin sensitivity, and improve safety in this setting. Methods: The study was an observational, retrospective cohort design. Clinical parameters including left ventricular ejection fraction (LVEF), cross-clamp time, age, serum albumin and C-reactive protein concentrations were collected from consenting patients who had undergone cardiac surgery and were prescribed postoperative warfarin. The warfarin dose index (WDI) was calculated for each patient from their international normalized ratio (INR) and warfarin dose, as a measure of sensitivity. Results: A total of 41 patients were recruited to the study. Logarithmically transformed WDI (log WDI) significantly correlated with LVEF, cardiopulmonary bypass (CPB) time, cross-clamp time, baseline INR and co-administration of amiodarone ( p < 0.05). When added to a linear regression model, LVEF and cross-clamp time produced a model that accounted for 41% of the variance in log WDI (R2 = 0.41), p = 0.0002). Applying a log WDI cutoff value of −0.349 discriminated between patients who develop an INR > 4 and those who do not, with a sensitivity of 75% and a specificity of 70%. Conclusions: This single-centre study has highlighted two risk factors for increased warfarin sensitivity post-cardiac surgery. Further research is needed to confirm these findings in a wider, more diverse population, and to validate this model.
- Open Access
- 23 April 2018
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 9 (7) , 355-366
Does the 5-HT1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?
Major depressive disorder (MDD) in older people is a relatively common, yet hard to treat problem. In this study, we aimed to establish if a single nucleotide polymorphism in the 5-HT1A receptor gene (rs6295) determines antidepressant response in patients aged > 80 years (the oldest old) with MDD. Nineteen patients aged at least 80 years with a new diagnosis of MDD were monitored for response to citalopram 20 mg daily over 4 weeks and genotyped for the rs6295 allele. Both a frequentist and Bayesian analysis was performed on the data. Bayesian analysis answered the clinically relevant question: ‘What is the probability that an older patient would enter remission after commencing selective serotonin reuptake inhibitor (SSRI) treatment, conditional on their rs6295 genotype?’ Individuals with a CC (cytosine–cytosine) genotype showed a significant improvement in their Geriatric Depression Score ( p = 0.020) and cognition ( p = 0.035) compared with other genotypes. From a Bayesian perspective, we updated reports of antidepressant efficacy in older people with our data and calculated that the 4-week relative risk of entering remission, given a CC genotype, is 1.9 [95% highest-density interval (HDI) 0.7–3.5], compared with 0.52 (95% HDI 0.1–1.0) for the CG (cytosine–guanine) genotype. The sample size of n = 19 is too small to draw any firm conclusions, however, the data suggest a trend indicative of a relationship between the rs6295 genotype and response to citalopram in older patients, which requires further investigation.
- 23 April 2018
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 9 (7) , 355-366
Open AccessDoes the 5-HT1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?
Major depressive disorder (MDD) in older people is a relatively common, yet hard to treat problem. In this study, we aimed to establish if a single nucleotide polymorphism in the 5-HT1A receptor gene (rs6295) determines antidepressant response in patients aged > 80 years (the oldest old) with MDD. Nineteen patients aged at least 80 years with a new diagnosis of MDD were monitored for response to citalopram 20 mg daily over 4 weeks and genotyped for the rs6295 allele. Both a frequentist and Bayesian analysis was performed on the data. Bayesian analysis answered the clinically relevant question: ‘What is the probability that an older patient would enter remission after commencing selective serotonin reuptake inhibitor (SSRI) treatment, conditional on their rs6295 genotype?’ Individuals with a CC (cytosine–cytosine) genotype showed a significant improvement in their Geriatric Depression Score ( p = 0.020) and cognition ( p = 0.035) compared with other genotypes. From a Bayesian perspective, we updated reports of antidepressant efficacy in older people with our data and calculated that the 4-week relative risk of entering remission, given a CC genotype, is 1.9 [95% highest-density interval (HDI) 0.7–3.5], compared with 0.52 (95% HDI 0.1–1.0) for the CG (cytosine–guanine) genotype. The sample size of n = 19 is too small to draw any firm conclusions, however, the data suggest a trend indicative of a relationship between the rs6295 genotype and response to citalopram in older patients, which requires further investigation.